R

Revolution Medicines

Clinical-stage oncology company developing RAS inhibitors

Senior Oncology Account Manager

Field SalesConfirmed live in the last 24 hours
Full-timeRemote in USA

About the Job

Requirements

  • A Master of Arts, Master of Science, Bachelor of Arts, or Bachelor of Science degree and 12–15+ years of biopharma industry experience.
  • 8–12+ years of prior experience in oncology product sales.
  • A proven track record of product launch success in the oncology therapeutic space.
  • Oral oncolytic product launch experience.
  • Experience launching oncology products with companion diagnostics.
  • A proven record of performance in highly competitive marketplaces.
  • A proven record of performance in solo-representative selling environments.
  • Demonstrated success operating in small- and midsize-biotechnology environments.
  • Ability to meet territorial travel requirements and travel to meetings, training, and programs as necessary.
  • Effectiveness in highly collaborative and cross-functional working environments.
  • A valid driver's license.
  • Must permanently reside in the territory for which they are accountable.
  • Approximately 50% travel is required.

Responsibilities

  • Effectively market Revolution Medicines’ product portfolio in the designated territory.
  • Exceed assigned performance goals for the territory by positioning the benefits and use of Revolution Medicines’ products for appropriate patients.
  • Direct efforts toward engagements that drive brand value and prioritize activities that positively impact patients.
  • Partner with key internal stakeholders to remove barriers to care and ensure every eligible patient receives timely access to Revolution Medicines’ products.
  • Flex between virtual and in-person engagements and develop business plans considering account communication preferences.
  • Analyze key market data points, turn insights into effective business planning, and implement plans by engaging key targets through call optimization and resource utilization.
  • Develop deep, sustained customer relationships across assigned accounts and proactively challenge customers through innovative, value-driven solutions.
  • Represent Revolution Medicines’ brands in a professional, compliant, ethical, and effective manner.
  • Maintain a thorough understanding of disease states, Revolution Medicines’ products, and relevant competitor offerings, and articulate value across digital, live, and other communication channels.
  • Maintain a comprehensive understanding of reimbursement processes and fulfillment pathways for oral oncolytics.
  • Manage the territory effectively and demonstrate strong selling competencies.
  • Creatively gain access to customers in the modern landscape.
  • Drive team effectiveness and shared-goal accomplishment by leveraging and sharing expertise and information.
  • Effectively manage territory resources and budget.
  • Comply with all laws, regulations, and policies governing the conduct of Revolution Medicines staff.
  • Embody corporate core values while cultivating an energized team culture focused on patient impact.

Desired Qualifications

  • Experience in the non-small cell lung cancer (NSCLC) oncology space.
  • An advanced degree such as an MBA, PharmD, or PhD.
  • Strong organization, planning, project management, technical, and analytical skills.
  • Relevant experience in areas such as sales operations, market research, or market access.
  • Ability to work independently to execute strategic and tactical plans under tight timelines.
  • Ability to deliver compelling presentations to individuals and groups, adapting messaging to maximize audience engagement.
  • High proficiency with Microsoft PowerPoint, Excel, and Word.

About the Company

Revolution Medicines

Clinical-stage oncology company developing RAS inhibitors

Revolution Medicines develops precision oncology drugs focused on cancers driven by RAS mutations. Its RAS(ON) inhibitors are small molecules that bind the active form of RAS to block cancer signaling, with candidates like Daraxonrasib (RMC-6236), Elironrasib (RMC-6291), and Zoldonrasib (RMC-9805) advancing in global Phase 3 trials. The company funds its research through collaborations, royalties, and upfront funding, and has not yet marketed a product. Its goal is to bring effective RAS-targeted therapies to patients and advance multiple candidates through late-stage trials toward approval, supported by strong cash reserves.

Company size
1,001-5,000
Company stage
IPO
Headquarters
Redwood City, CA
Founded
2014

Recently Posted Jobs

Explore more opportunities at Revolution Medicines

See more jobs